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Simultaneous expression of highly homologous RLN1 and RLN2 genes in prostate impairs their accurate
delineation. We used PacBio SMRT sequencing and RNA-Seq in LNCaP cells in order to dissect the
expression of RLN1 and RLN2 variants. We identiﬁed a novel fusion transcript comprising the RLN1 and
RLN2 genes and found evidence of its expression in the normal and prostate cancer tissues. The RLN1RLN2 fusion putatively encodes RLN2 isoform with the deleted secretory signal peptide. The identiﬁcation of the fusion transcript provided information to determine unique RLN1-RLN2 fusion and RLN1
regions. The RLN1-RLN2 fusion was co-expressed with RLN1 in LNCaP cells, but the two gene products
were inversely regulated by androgens. We showed that RLN1 is underrepresented in common PCa cell
lines in comparison to normal and PCa tissue. The current study brings a highly relevant update to the
relaxin ﬁeld, and will encourage further studies of RLN1 and RLN2 in PCa and broader.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NCND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Relaxin is a mammalian hormone that is involved in reproduction. As the name suggests, relaxin is the component of serum that
causes the relaxation of the pubic ligament in pregnant female
prior to delivery (Fevold et al., 1930; Hisaw, 1926). The human

Abbreviations: CSS, CCS; RLN1, RLN2; RLN1-RLN2, RLN1-RLN2-1; RLN1-RLN2-2,
PCa; SMRT, RNA-Seq; PacBio, SMRTBell; MISO, EST; FBS, DHT; R1881, BAM; shAR,
shRLN2; shNT, RFP; dox, Hg19; Hg38, TCGA; TPM, AR; PSA, RNF6.
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relaxin gene was ﬁrst isolated from a cDNA library from the corpus
luteum, and later conﬁrmed and characterized by mass spectrometry (Hudson et al., 1984; Stults et al., 1990). In apes and humans,
the relaxin gene underwent a duplication generating two relaxin
genes with high sequence similarity, relaxin-1 (RLN1) and relaxin-2
(RLN2). (Arroyo et al., 2014; Crawford et al., 1984). RLN1 mRNA is
expressed in the prostate, but RLN1 peptide has never been isolated
and its function has not been explored yet (Garibay-Tupas et al.,
2000; Gunnersen et al., 1996). The ovaries and prostate are the
two major sources of RLN2 in humans. The expression of RLN2 in
ovaries is intermittent and increases during the luteal phase of the
menstrual cycle, with highest levels being produced by the corpus
luteum during pregnancy (Ivell et al., 1989). In men, RLN2 is produced continuously by the prostate, and accumulates in the seminal ﬂuid to increase sperm motility (Carrell et al., 1995; Winslow
et al., 1992). Outside normal physiology, RLN2 is a promoter of
cancer progression in several different types of cancers (Nair et al.,

http://dx.doi.org/10.1016/j.mce.2015.10.011
0303-7207/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncnd/4.0/).
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culture incubator at standard conditions (37  C, 5% CO2).

2012). In prostate cancer (PCa), RLN2 was shown to promote tumor
growth and vascularisation, and was regulated by androgens (Feng
et al., 2010; Silvertown et al., 2006; Thompson et al., 2010, 2006).
Inhibition of RLN2 signalling by a peptide antagonist in PCa showed
promising therapeutic efﬁcacy in preclinical studies (Feng et al.,
2010; Neschadim et al., 2014).
High homology between RLN1 and RLN2 in the context of
simultaneous expression in prostate tissue hinders the accurate
characterization and functional study of individual relaxin genes in
the prostate. In addition to the canonical sequences, a 101 bp longer
alternatively spliced variant of RLN2 was discovered in the prostate
tissue (Gunnersen et al., 1996). There are several more transcript
variants predicted by automated computational analysis that are
supported by mRNA and EST data as annotated in the Aceview
database (Thierry-Mieg and Thierry-Mieg, 2006). Standard mRNA
determination methods like qPCR, microarray, and RNA-Seq all
largely depend on gene annotation databases which are incomplete, and change frequently with the identiﬁcation of novel transcripts. Recent development of PacBio single molecule real time
(SMRT) sequencing techniques aids the identiﬁcation of transcript
variants due to the longer read lengths produced by this platform
(Eid et al., 2009). Although PacBio data are inherently error-prone, a
level of consensus accuracy can be achieved by multiple sequencing
passes around the SMRTBell libraries. Circular consensus sequences
(CCS) are derived from the long, raw reads providing sufﬁcient
read-of-insert depth of coverage to improve CCS read accuracy to
>98% (Travers et al., 2010). Paired-end RNA-Seq can also be used to
characterize the expression of alternatively spliced genes using a
Sashimi Plot - this implements a mixture of isoforms (MISO) algorithm and displays alternative exon usage by splice junction
reads as arcs connecting a pair of exons (Katz et al., 2015).
The aim of the present study was to use PacBio derived long
cDNA SMRT sequencing in LNCaP cells in order to dissect the
expression of RLN1, RLN2, and their transcript variants, and to
identify unique RLN1 and RLN2 regions for the purpose of more
accurate characterization. We report on a novel abundantly
expressed fusion transcript between RLN1 and RLN2. The RLN1RLN2 fusion putatively encodes an alternative RLN2 isoform with
an altered signal sequence domain that potentially changes the
mode of secretion. We inspected publically available RNA-Seq
datasets for evidence of RLN1-RLN2 fusion expression in normal
and PCa tissues. The fusion has substantial sequence overlap with
RLN1 and RLN2, however we designed unique RLN1-RLN2 fusion
and RLN1 qPCR primers, and determined their expression in common PCa cell lines as well as deﬁned their androgen regulation.

Clontech SMARTer cDNA Synthesis. Long cDNA was prepared from
1 mg of DNase-treated LNCaP total RNA using the Clontech SMARter
PCR Synthesis Kit (Clontech Laboratories, Mountain View, CA, USA).
Second-strand cDNA was prepared in sixteen PCR reactions with
2 ml undiluted ﬁrst-strand cDNA, 0.24 mM Clontech 50 PCR Primer
IIA and KAPA HiFi HotStart ReadyMix (Kapa Biosystems, Inc., Wilmington, MA, USA) for 14 cycles in the standard SMARTer PCR
cycling conditions. The second-strand PCR production was puriﬁed
and concentrated through a single QIAquick PCR Puriﬁcation Kit
(QIAGEN Sciences, Germantown, MD, USA) and the concentration
was determined using the Qubit dsDNA HS Assay Kit (Life Technologies, Grand Island, NY, USA). cDNA-Capture and Ampliﬁcation.
The cDNA was hybridized with a custom NF1 probe set (Gutmann
et al., 2013). Here, 780 ng of the cDNA library was mixed with
5 mg Cot-1 DNA (Invitrogen, Carlsbad, CA, USA) and 100 ng of NF1
probe. Hybridization was carried out in the presence of NimbleGen
hybridization buffers (Roche NimbleGen, Madison, WI, USA) and
processed per NimbleGen's SeqCap EZ Library SR user guide instructions. The solutions were denatured and allowed to hybridize
at 47  C for 72 h. Post hybridization and PCR steps are described in
Cabanski et al. (2013). In brief, we performed 14 PCR cycles for the
enriched cDNA library. Paciﬁc Biosciences Sample Prep and
Sequencing. Captured cDNA was converted into a 2 kb Paciﬁc Biosciences (Paciﬁc Biosciences of California, Inc., Menlo Park, CA, USA)
library, according to the standard protocol using 500 ng of captured
genomic DNA or cDNA and the DNA Template Prep Kit 2.0 (250 bp e
3 Kb). The resulting libraries were prepared for sequencing with the
P4 polymerase and C2 chemistry using the MagBead protocol and
DNA/Polymerase Binding Kit P4. The libraries complexes were
prepared with 30 pM library and a 10:1 ratio of P4 DNA polymerase
to library. Each library complex was sequenced on two SMRT cells
with 180 min movie lengths using the MagBead Standard Seq v2
protocol. Circular consensus sequences were called using the
ReadsOnInsert_CCS protocol through the SMRT Portal interface.
The minimum full pass and minimum predicted accuracy ﬁlters
were set at 2 and 90%, respectively. Detection of RLN1-RLN2 fusion.
The RLN1-RLN2 fusion was identiﬁed from full-length CCS reads
spanning the length of the entire transcript. For a transcript to be
reported, we required at least two independent CCS reads to
contain identical nucleotide sequences over the entire length of the
transcript.

2. Materials and methods

2.3. Analysis of RNA-Seq

2.1. Cell lines

RNA-Seq from LNCaP cells. LNCaP cells were seeded in a 10 cm
culture dish and treated with 10 nM dihydrotestosterone (DHT) as
described in the section ‘Short-term androgen deprivation assay’
below. Total RNA was isolated using the Norgen RNA Plus extraction
kit (Norgen, Acacia Ridge, QLD, AU). RNA-Seq was carried out on
total RNA using an Illumina TruSeq Stranded mRNA Sample Prep Kit
with Set A indexes (Illumina, Scoresby, VIC, AU) and sequenced on
Illumina HiSeq2500 v4.0 platform (Kinghorn Centre for Clinical
Genomics (KCCG), Sydney, NSW, AU). Sequencing reads were
generated by quality trimming using Trimgalore v.03.7 (Babraham
Institute,
http://www.bioinformatics.babraham.ac.uk/projects/
trim_galore/) and aligned to the GRCh38/hg38 genome using
STAR v.2.4.0j (Dobin et al., 2013). RNA-Seq from normal and PCa
tissue. Transcript splice-site usage was assessed on RNA-Seq data
sets comprising 14 PCa tumors and adjacent benign tissue (Ren
et al., 2012). RNA-Seq reads were mapped using Tophat2
(GRCh37/Hg19 assembly), and splice sites were visualized using

Immortalized prostate epithelial cells RWPE-1 (ATCC CRL11609) were grown in keratinocyte serum-free media supplemented with recombinant human epidermal growth factor (5 ng/
ml ﬁnal concentration) and bovine pituitary extract (50 ng/ml).
Immortalized prostate epithelial cells BPH-1, HPR-1, and PCa cell
lines PC-3 (ATCC CRL-1435), 22RW1 (ATCC CRL-2505), DU145
(ATCC HTB-81), LNCaP (ATCC CRL-1740), C4-2B (from Dr Leland
Chung, Cedars-Sinai Medical Center, USA), DuCaP (from Dr Matthias Nees, Faculty of Medicine, Turku University, Finland) were
cultured in RPMI1640 supplemented with 5% FBS. LAPC4 cells were
grown in IMDB medium supplemented with 5% FBS. HEK293T were
cultured in high-glucose DMEM, supplemented with 2 mM Lglutamine and 1 mM sodium pyruvate and 10% heat inactivated
FBS. All media and supplements were sourced from Gibco (Life
Technologies, Mulgrave, VIC, AU). All cells were grown in a cell

2.2. PacBio sequencing
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indexed BAM ﬁles and the Integrative Genomics Viewer (Kim et al.,
2013; Robinson et al., 2011). IlluminaHiSeq_RNASeqV2 from 193
samples generated by the TCGA Research Network were accessed at
http://cancergenome.nih.gov/(September 4, 2013) and were analysed as previously described (Li et al., 2010). Correction of the RLN1RLN2 fusion sequence informed by Illumina RNA-Seq from LNCaP cells.
We generated the bowtie (Langmead et al., 2009) index ﬁles for the
corrected RLN1-RLN2-2 fusion transcript sequence (genome assembly GRCh38/Hg38 matched). The reads from Illumina RNA-Seq
from LNCaP cells were then aligned to the RLN1-RLN2-2 fusion
transcript and the bam ﬁle was generated and visualized in RNASeqBrower (An et al., 2015).
2.4. Inducible stable shRNA cell line models
Lentivirus particles were generated in HEK 293T host cells
transfected with X-tremeGENE HP DNA Transfection Reagent
(Roche, Sydney, NSW, AU) and inducible lentiviral pTRIPZ shRNA
plasmids targeting either the androgen receptor (AR) (shAR), RLN2
(shRLN2), or a negative control (shNT) (Thermo-Fisher Scientiﬁc,
Richlands, QLD, AU). The pCMV-8.2R lentiviral packaging plasmids
and pCMV-VSVG were kindly provided by Dr Brett Hollier
(Queensland University of Technology, Brisbane, QLD, AU). Virus
particles were collected 48 h and 72 h after transfection, and
ﬁltered through 45 mm ﬁlters. Target cells (LNCaP) were infected
with the virus supernatant and 8 mg/ml protamine sulphate (SigmaeAldrich, Castle Hill, NSW, AU). Transfected cells were then
selected with 2 mg/ml Puromycin Dihydrochloride (Life Technologies, Mulgrave, VIC, Australia). We observed some cells expressing
red ﬂuorescent protein (RFP) indicating inducible promoter
leakage; therefore we used an Astrios EQ cell sorter (Beckman
Coulter, Lane Cove, QLD, Australia) to remove cells with leaky
inducible promoter.
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LNCaP cells were seeded onto T25 ﬂasks and incubated in RPMI
1640 þ 5% FBS for 3 days. The medium was then changed to RPMI
1640 supplemented with 5% CSS, and incubated with or without
1 mg/ml of doxycyline (dox) for 48 h. The medium was then supplemented with 10 nM DHT, and incubated for 48 h. The reference
group was kept in CSS.
2.6. Quantitative real-time PCR
Total RNA was extracted using the RNAeasy Kit (Qiagen, Chadstone Centre, VIC, AU) before reverse transcription with SuperScript
III Reverse Transcriptase (Life Technologies, Mulgrave, VIC, AU)
according to the manufacturer's protocol. Subsequent quantitative
PCR (qPCR) was carried out on the ViiA7 or 7900HT Real-Time PCR
System (Life Technologies, Mulgrave, VIC, AU) with SYBR Green, or
using Universal TaqMan detection (Life Technologies, Mulgrave,
VIC, AU). Gene expression was determined using the 2DDCt
method, and normalized to the housekeeping gene RPL32. Data is
expressed relative to the reference group. Experiments were
repeated a minimum of 3 times. Primer sequences are detailed in
the Supplementary Table 1.
2.7. Statistical analysis
Results are representative of at least three independent experiments with triplicate samples generating similar ﬁndings. Differences between experimental groups were statistically evaluated by
multiple t-tests, followed by the HolmeSidak test for multiple
comparisons. p  0.05 was considered statistically signiﬁcant.
Statistical analysis was performed using Prism 6 (GraphPad Software Inc.).
3. Results

2.5. Inhibition of androgen signalling

3.1. Identiﬁcation of novel RLN1-RLN2 fusions in PCa

Short-term androgen deprivation assay. LNCaP cells were seeded
into T25 ﬂasks, and incubated in RPMI1640 þ 5% FBS for 3 days. The
medium was then changed to RPMI 1640 supplemented with 5%
charcoal stripped serum (CSS) and incubated for 2 days, then
changed to RPMI 1640 supplemented with 10 nM DHT or 1 nM
R1881, and incubated for 48 h with DHT top-up at 24 h. The
reference group was kept in CSS. Long-term androgen deprivation
assay. LNCaP cells were seeded into T25 ﬂasks and incubated in
RPMI 1640 þ 5% FBS for 3 days. The medium was then changed to
RPMI 1640 supplemented with 5% CSS, and incubated for 10 days
with medium changes every 3 days. Inducible AR knock-down.

To comprehensively identify RLN1 and RLN2 transcript variants, we used long cDNA-Cap and SMRT sequencing in LNCaP
cells, and queried for circular consensus sequences (CCSs) that
mapped to the RLN1-RLN2 locus. We found CCSs identical to the
annotated RLN1 gene, but interestingly, no CCS corresponded
to the annotated RLN2 gene (GENCODE Version 19). Instead,
the search retrieved sequences of two longer RLN2 transcript
variants which were fused to the RLN1 gene, generating two
fusion transcripts RLN1-RLN2-1 and RLN1-RLN2-2 (Fig. 1,
Supplementary Fig. S1). The inherent error-proneness of the
SMRT sequencing technology hindered the determination of the

Fig. 1. Identiﬁcation of the RLN1-RLN2 fusion in LNCaP cells using SMRT sequencing. The ﬁgure was extracted from the UCSC Genome Browser where the circular consensus
sequences (CCS) of RLN1 and RLN2 identiﬁed by SMRT sequencing were aligned to the RLN1/RLN2 genomic locus using BLAT tool. GENCODE Version 19 annotated RLN1 and RLN2
transcript variants are shown in black. Combined CCS sequences of RLN1 are shown in orange and RLN1-RLN2 fusion CCS transcripts in blue. The arrowed-line represents introns and
show directionality of the transcripts. The golden rectangles show an overlay between the annotated RLN1 and RLN2 and the transcripts identiﬁed by SMRT sequencing. (For
interpretation of the references to color in this ﬁgure caption, the reader is referred to the web version of this article.)
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precise nucleotide sequence of the fusion transcripts. Therefore,
we aligned the sequences of the novel fusion transcripts RLN1RLN2-1 and RLN1-RLN2-2 to the human genome assembly
GRCh38/hg38 using the Blat tool in the UCSC genome browser
(Kent, 2002; Kent et al., 2002). The sequences of the fusion
transcripts were then corrected to match the genomic sequence.
In order to increase the degree of certainty of the fusion transcript sequence, we mapped individual sequencing reads generated by a standard Illumina paired-end RNA-Seq from LNCaP cells
to the corrected RLN1-RLN2-2 fusion sequence. We utilized a
recently in-house developed RNASeqBrowser tool (An et al.,
2015) and observed that the raw sequencing reads perfectly
aligned to the corrected sequence of the RLN1-RLN2-2 fusion,
conﬁrming its legitimacy (Supplementary Fig. S2). The mapping
of raw sequencing reads highlighted only 3 differences in the
nucleotide sequence of the RLN1-RLN2-2 fusion that could be
ascribed to the difference between the human genome assembly
GRCh38/hg38 and LNCaP genome (Supplementary Fig. S2). To
additionally conﬁrm the expression of the RLN1-RLN2 fusion
transcripts, we analysed Illumina paired-end RNA-Seq from
LNCaP cells using Sashimi Plot representation of RNA-Seq data in
the Integrative Genomic Viewer. Sashimi Plots display alternative
exon usage by drawing splice junction reads as arcs connecting a
pair of exons (Katz et al., 2015). Both novel fusion transcripts
RLN1-RLN2-1 and RLN1-RLN2-2 were clearly observed in the
Sashimi Plot of RNA-Seq from LNCaP cells (Fig. 2A). We then
inspected Ren et al. RNA-Seq data comprising PCa tumors and
adjacent benign tissue, and found similar splice junction reads
between exons of novel fusion transcripts to those in LNCaP cells,
suggesting broader representation of the RLN1-RLN2 fusion
(Fig. 2B, C) (Ren et al., 2012). In support of the newly identiﬁed
RLN1-RLN2 fusion transcript the sequence of a similar longer
RLN2 variant was recently predicted by an automated computational analysis that was supported by mRNA and EST evidence
(accession
number:
XM_011518003.1,
March
2015)
(Supplementary Fig. S3).
3.2. Novel RLN1-RLN2 fusion has an alternative putative ORF
The novel RLN1-RLN2 fusion transcripts contained incomplete
nucleotide sequences of both RLN1 and RLN2 and acquired novel
exons in the intergenic region between the genes. In order to
investigate whether the RLN1-RLN2 fusion transcripts encode novel
putative open reading frames (ORF) we analysed the sequences
with the Translate Tool (Expasy, http://web.expasy.org/translate/).
The shorter RLN1-RLN2-1 fusion transcript putatively translated
into a RLN2 peptide with a truncated C-peptide and an A-chain, and
was therefore not considered for further investigation. The analysis
of the longer RLN1-RLN2-2 fusion transcript predicted a novel RLN2
isoform with an alternative start codon within a novel exon of the
fusion (Fig. 3). The new putative RLN2 isoform contained intact
functional domains of RLN2 (B-chain, C-peptide and A-chain), but
lost the entire signal sequence that is essential for its secretion via
the endoplasmic reticulum (ER)-Golgi secretory pathway (Fig. 3).
Instead, the signal sequence was replaced by a short leader peptide
MNTSKAVA (Fig. 3). We also unveiled an LNCaP speciﬁc single
nucleotide polymorphism in the C-peptide region of RLN2 (and of
RLN1-RLN2-2) that affected the change of amino acid from

isoleucine to asparagine
(Supplementary Fig. S2).
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in

the

sequence

KKLI/NRNR

3.3. Identiﬁcation of unique RLN1-RLN2 fusion and RLN1 regions
The RLN1-RLN2-2 fusion showed a signiﬁcant overlap with the
annotated RLN1 and RLN2 genes. In order to characterize the
expression of the fusion, we aligned both novel fusion transcripts
using the BLAT tool in the USCS genome browser (Kent, 2002; Kent
et al., 2002), and designed the qPCR primers in unique RLN1-RLN2-2
regions. The forward primer for speciﬁc detection of RLN1-RLN2-2
fusion was designed to span the junction between the novel exon of
the fusion and the downstream fusion exon that is shared with the
annotated RLN2. The reverse primer was designed in a region
shared by RLN2 and RLN1-RLN2-2 fusion (Fig. 4A). Similarly, we
designed qPCR primers in the RLN1 unique region (Fig. 4A). In order
to test the speciﬁcity of the primers, we stably transfected LNCaP
cells with a doxycycline inducible lentiviral vector encoding shRNA
targeting the annotated RLN2 gene (shRLN2). LNCaP cells stably
expressing non-targeting shRNA (shNT) were used as a control. The
addition of doxycycline in shNT cells had no effect on the expression of RLN1-RLN2-2 fusion, whereas the addition of doxycycline to
shRLN2 cells resulted in a signiﬁcant decrease in the levels of RLN1RLN2-2 fusion (Fig. 4B). These results conﬁrmed that the novel exon
of the fusion is linked to the exon of the annotated RLN2 gene. RLN2
knock-down (shRLN2) had no effect on RLN1 levels. Although the
expression of RLN1 decreased with doxycycline treatment, we
observed no difference between the control (shNT) and shRLN2
cells, conﬁrming the speciﬁcity of RLN1 primers (Fig. 4C).
3.4. Underrepresentation of RLN1 in PCa cells
The RLN1-RLN2-2 fusion and RLN1 are overlapping same strand
transcripts (Fig. 1). We thus predicted an association between the
expression of RLN1 and RLN1-RLN2-2 fusion. We ﬁrst determined
the expression of RLN1 in 3 normal and 7 PCa cell lines. RLN1 was
abundantly expressed only in LNCaP cells, whereas in other PCa
cells, the expression was >80-fold lower (Fig. 5A). Similarly, the
expression of the RLN1-RLN2-2 fusion was highest in LNCaP cells,
and marginal in the other PCa cells (Fig. 5B). The unexpected low
expression of RLN1 in common PCa cell lines was a surprising
observation as RLN1 is expressed in prostate tissue (Hansell et al.,
1991). We found further evidence of prostate tissue speciﬁc
expression of RLN1 by accessing the Su et al. GeneAtlas microarray
dataset (Fig. 5C) (Su et al., 2004). Next, we examined a publically
available TCGA RNA-Seq dataset from normal and PCa tissue samples to investigate whether the expression of RLN1 is limited to
normal prostate tissue. We showed that both normal and PCa tissue
expressed high levels of RLN1 (Fig. 5D). The median expression of
RLN1 in normal prostate tissue was 42.5 transcripts per million
reads (TPM) and 12.7 TPM in PCa tissue.
3.5. RLN1-RLN2 fusion and RLN1 are inversely regulated by
androgens
The expression of RLN2 has been shown to be negatively regulated by androgens in LNCaP cells (Thompson et al., 2006). The
androgen responsiveness of RLN2 led us to investigate the androgen

Fig. 2. RLN1-RLN2 fusion exons were observed in RNA-Seq data from LNCaP and from normal and PCa tissues. Expression of transcripts at the RLN1/RLN2 genomic locus is represented by a blue wiggle plot (RNA-Seq coverage). Arcs in the RNA-Seq coverage plot represent the junction between exons and the number informs the quantity of split reads
between the exons. Black arcs show split reads between the exons of novel fusion transcripts RLN1-RLN2-1 and RLN1-RLN2-2 and the red arcs show the exoneexon junctions that
were not identiﬁed by SMRT sequencing in LNCaP. The shadowed area shows an overlay of RLN1 and novel RLN1-RLN2 fusion transcripts with the junctions from RNA-Seq datasets
generated using Sashimi Plot Tool and extracted from the Integrated Genome Viewer. A. GENCODE v.19 annotated RLN1 and RLN2 transcript variants (black) and RNA-Seq data from
LNCaP cells. B. RNA-Seq data from Ren et al. (2012) study from benign prostate tissue and C. PCa tissue. (For interpretation of the references to color in this ﬁgure caption, the reader
is referred to the web version of this article.)
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Fig. 3. RLN1-RLN2-2 fusion encodes a putative RLN2 isoform without a signal peptide. Novel fusion RLN1-RLN2-2 is aligned with the currently annotated RLN2 peptide. The region
with an alternative start codon is enlarged below. The entire signal sequence is deleted in the novel putative RLN2 isoform however the functional B-chain, C-peptide and A-chain
are unchanged (downstream C-peptide and A-chain not shown).

regulation of the RLN1-RLN2-2 fusion and RLN1. Charcoal-stripped
fetal bovine serum (CSS) was used to grow LNCaP cells in the
absence of androgens for a period of 10 days. The removal of androgens resulted in a steady increase in the levels of the RLN1RLN2-2 fusion (Fig. 6A). Although the levels of RLN1 were higher
in the absence of androgens, the increase was marginal in comparison to the RLN1-RLN2-2 fusion (Fig. 6A). To further conﬁrm that
the increase in expression of the RLN1-RLN2-2 fusion was a result of
androgens, we performed a similar experiment where LNCaP cells
were ﬁrst grown in CSS for 2 days followed by the 2 day treatment
with androgens (10 nM DHT or 1 nM R1881). The treatment of
LNCaP cells with androgens abolished the increase in expression of
the RLN1-RLN2-2 fusion (Fig. 6B). This androgen suppression

resulted in 60e75% lower levels of RLN1-RLN2-2 fusion in androgen
treated cells compared to control (Fig. 6B). Contrary to the RLN1RLN2-2 fusion, the addition of androgens resulted in upregulation of the expression of RLN1, indicating an inverse
androgen regulation of the transcripts (Fig. 6C). To further assure
that the inverse androgen regulation of RLN1-RLN2-2 and RLN1 is a
result of androgen directed signalling, we speciﬁcally inhibited the
AR by doxycycline induced shRNA knock-down (shAR). DHT
treatment in control cells (shNT) suppressed the expression of
RLN1-RLN2-2 fusion in both doxycxyline induced and non-induced
cells (Fig. 6D). This suppression was still evident in non-induced
shAR cells, but doxycycline induced AR knock-down impaired this
suppression, conﬁrming that androgen signalling down-regulates

Fig. 4. Identiﬁcation of unique sequences of RLN1-RLN2-2 fusion and of RLN1. A. GENCODE V.19 RLN1 and RLN2 transcripts (black) are aligned to novel fusion transcripts RLN1-RLN21 and RLN1-RLN2-2. The canonical exons of RLN1 and RLN2 are overlaid to the fusion transcripts (gold rectangle) demonstrating the shared and unique regions of the transcripts. The
arrows above transcripts represent the position of unique primer sets and the star represent the shRNA target sequence. The expression of B. RLN1-RLN2-2 and C. RLN1 after the
doxycycline (DOX, 250 ng/ml) inducible knock-down of RLN2. (n ¼ 3; error bars, SE), *p < 0.05, ***p < 0.005. (For interpretation of the references to color in this ﬁgure caption, the
reader is referred to the web version of this article.)
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Fig. 5. Co-expression of RLN1 and RLN1-RLN2-2 fusion and underrepresentation of RLN1 in PCa cell lines. Relative gene expression of A. RLN1 and B. RLN1-RLN2-2 in common PCa
cell lines (n ¼ 3; error bars, SE). C. The expression of RLN1 in a publically available high-density microarray dataset from different human tissues (Su et al., 2004). The vertical line
represents a 10 value of the Median expression in all tissues. The expression value for each tissue is an average of 2 microarray experiments with 11 probes for RLN1. D. Expression
of RLN1 determined from a TCGA RNA-Seq dataset from 36 benign prostate and 157 PCa tissues. The scatter plot represents expression values (transcripts per million, TPM) in each
tissue sample; M (Median)

the levels of RLN1-RLN2-2 (Fig. 6D). Contrary to RLN1-RLN2-2, the
expression of RLN1 was increased after DHT treatment in control
cells, but this increase was suppressed by AR knock-down (Fig. 6E).
The changes in expression of the androgen responsive gene PSA
were determined in all assays to conﬁrm that the levels of androgens were depleted, or that the AR knock-down was efﬁcient, and
AR signalling decreased (Supplementary Fig. S4).
4. Discussion
In this study we used SMRT sequencing of full length RNA
transcripts in PCa LNCaP cells in order to dissect the expression of
RLN1, RLN2, and their transcript variants, and to identify unique
sequences of RLN1 and RLN2 for more accurate characterization. We
report on a novel abundantly expressed fusion transcript
comprising the RLN1 and RLN2 genes which encodes a putative
RLN2 isoform with an altered signal sequence domain that potentially modiﬁes its mode of secretion. By employing a Sashimi Plot
visualization of RNA-Seq data, we showed the presence of the

unannotated fusion in both normal and PCa tissue. We designed
unique RLN1-RLN2 fusion and RLN1 qPCR primers, and found that
the RLN1-RLN2 fusion and RLN1 were co-expressed in various PCa
cell lines but inversely regulated by androgens in LNCaP cells. We
showed that RLN1 was surprisingly underrepresented in PCa cell
lines in comparison to normal and PCa tissue.
We have identiﬁed a novel longer RLN2 transcript variant representing a fusion between RLN1 and RLN2 in LNCaP cells (Fig. 1).
Despite the use of northern blotting in previous PCa studies, longer
RLN2 transcripts have not been observed (Ivell et al., 1989). We have
however used a recent state of the art SMRT sequencing technique
and obtained RLN1-RLN2 fusion sequences in PCa cells (Fig. 1).
Additionally, we have observed fusion speciﬁc exons in RNA-Seq
from normal and PCa tissues (Fig. 2B, C). Further evidence of the
RLN1-RLN2 fusion comes from a recent study where several longer
RLN2 transcripts were predicted from de novo assembly of 7256
RNA sequencing (RNA-seq) libraries of tumors, normal tissue, and
cell lines from 25 independent studies (Supplementary Fig. S5)
(Iyer et al., 2015). The size of the fusion transcript was 2 kbp,
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Fig. 6. RLN1-RLN2-2 and RLN1 are inversely regulated by androgens. A. Relative gene expression of RLN1-RLN2-2 and RLN1 determined in a long-term androgen deprivation assay;
RLN1-RLN2-2 (square), RLN1 (circle). B. Relative gene expression of RLN1-RLN2-2 and C. RLN1 determined in a short-term androgen deprivation assay; CSS (absence of androgens),
DHT (physiological androgen, 10 nM), R1881 (synthetic androgen, 1nM), (n ¼ 3, error bars, SE). ****p < 0.001. D. Relative gene expression of RLN1-RLN2-2 and E. RLN1 in LNCaP cells
stably expressing doxycycline (dox) inducible non-targeting shRNA [shNT] or shRNA targeting AR [shAR] determined in a short-term androgen deprivation assay; CSS (absence of
androgens), DHT (physiological androgen, 10 nM), (n ¼ 3, error bars, SE). ****p<0.001; ns -non signiﬁcant.

making it twice the size of either RLN1 or RLN2. The expression and
tissue speciﬁcity of RLN1, RLN2, and their variants, has been previously investigated using cloning techniques from cDNA libraries,
northern blotting and qPCR (Garibay-Tupas et al., 2000; Gunnersen
et al., 1996; Hudson et al., 1984). Interestingly, initial northern blots
performed in RNA samples from ovaries with RLN2 speciﬁc probes
revealed a longer transcript of the similar size (2 kbp) as the fusion
transcript we identiﬁed in PCa cells LNCaP (Hudson et al., 1984). The
longer variant was considered to be a potentially longer primary
RLN2 mRNA species that was probably truncated into a mature
RLN2 by cleavage in the alternative polyadenylation site but this
had not been explored further. In another study, the longer 2 kbp
variant of RLN2 was conﬁrmed by northern blotting in ovaries, and
interestingly the expression was found to be increasing with the
luteal phase of the menstrual cycle (Ivell et al., 1989). Thus, the
evidence from the literature indicates that the longer RLN2 transcripts observed in the ovarian samples resemble the size of the
novel RLN1-RLN2 fusion transcript identiﬁed in our study. Therefore, it would be interesting to investigate the expression of the
RLN1-RLN2 fusion in ovaries.
The novel RLN1-RLN2 fusion putatively encodes a RLN2 isoform
that retains all the functional domains of RLN2, but lacking the
signal sequence responsible for secretion through the ER-Golgi
complex and release into the cell exterior. The lack of a secretory
signal could therefore obstruct the secretion of the RLN2 peptide
from the cells. However, some secretory proteins lack the signal
peptide and utilize alternative secretory pathways. For example,
IL1b is a secretory inﬂammatory cytokine without a signal sequence
and was consequently not found in the ER or Golgi but instead was
translated by free polyribosomes (Lopez-Castejon and Brough,
2011). One of the proposed secretory pathways of IL1b included
shedding by microvesicles or exosomes. Interestingly, prostate
gland epithelial cells are known to secrete vesicles called prostasomes into the seminal ﬂuid (Sahlen et al., 2002). Thus, it is possible

that the fusion encoded RLN2 isoform is secreted from prostate
cells enclosed in prostasomes. The membrane enclosed RLN2
would have limited functionality in the seminal ﬂuid and would be
protected from degradation until reaching the target tissue.
Opposing to the hypothesis of the prostasomal secretion of the
fusion encoded RLN2, the RLN2 peptide identiﬁed in the seminal
ﬂuid was identical to the one isolated from the ovaries thus without
a fusion speciﬁc alternative MNTSKAVA leader sequence (Winslow
et al., 1992). However in the mentioned study, RLN2 peptide was
enriched from the sample of seminal ﬂuid with an RLN2 antibody
that might have failed to recognize the fusion encoded RLN2. In
order to further investigate the cellular trafﬁcking and function of
the novel fusion encoded RLN2 isoform we aim to determine the
precise nucleotide sequence of the fusion by sequencing of the
cDNA clones and investigating its role in the next phase of our
study.
The RLN1-RLN2 fusion has a signiﬁcant overlap with RLN1 and
RLN2 and thus unique regions are severely restricted (Figs. 1 and 3),
providing technical challenges for the accurate characterization of
their expression. The fusion transcript overlapped the 30 end of the
ﬁrst and the 50 end of the second RLN1 exon, which represents a
prime template for qPCR primers to be able to discriminate between mRNA and genomic DNA. However in the case of RLN1,
primers designed near the exon junction would not be able to
discriminate between RLN1 and RLN1-RLN2 fusion transcripts.
Therefore we designed qPCR primers in unique RLN1 regions at the
30 end of the second exon. RLN1 speciﬁc primers were used previously, however their speciﬁcity was determined based on testing of
different primer sets and selecting for those that were able to
discriminate between the expression of RLN1 in corpus luteum and
prostate tissue. For instance, RLN1 has been shown to be expressed
in prostate tissue but not in the corpus luteum by northern blotting
(Garibay-Tupas et al., 2000; Gunnersen et al., 1996). Conﬁrming the
validity of our unique RLN1 region, the reverse primer for RLN1 in
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both studies was designed in a region that we identiﬁed to be
unique for RLN1 (Fig. 4).
Using our speciﬁc RLN1 qPCR primers, we observed that RLN1
mRNA is underrepresented in PCa cell lines. We found that RLN1
was abundantly expressed only in LNCaP cells out of the 3 normal
and 7 PCa cell lines tested. However, RLN1 has been shown to be
expressed in the prostate tissue (Gunnersen et al., 1996; Hansell
et al., 1991). Speciﬁcally, we showed that RLN1 is a unique prostate tissue transcript (Fig. 5C) and abundantly expressed in normal
prostate and cancer tissue (Fig. 5D). Thus, LNCaP cells best reﬂect
the RLN1 expression observed in PCa and is the most relevant cell
line for the use in further studies of RLN1 biology.
Androgens and androgen-regulated genes are important in the
onset and progression of PCa. We observed that the RLN1-RLN2
fusion is down-regulated by androgens (Fig. 6B). The suppression of
annotated RLN2 was previously shown in LNCaP cells and tissues,
however the primers used were unable to distinguish between
RLN2 and the RLN1-RLN2 fusion (Thompson et al., 2006). In the later
study, the RLN1-RLN2 fusion transcript might have contributed to
the majority of the qPCR signal considering the abundant expression of the fusion in LNCaP cells. Androgen regulation of RLN1 has
not been previously shown, although Xu et al. showed AR binding
upstream of the RLN1 gene, and co-regulation of RLN1 expression
by AR and RNF6 (Xu et al., 2009). We demonstrate that RLN1 was
up-regulated by androgens (Fig. 6C, E). Thus, we show here that
although both RLN1 and the RLN1-RLN2 fusion transcript initiate
from the same genomic locus and share parts of the genomic code,
they are nevertheless inversely regulated by androgens. Since the
transcription start site of RLN1 is located just upstream of the RLN1RLN2 fusion, it would be interesting to investigate to what extent
the transcription of RLN1 directly controls the expression of the
fusion transcript.
In conclusion, our study implemented a state of the art SMRT
sequencing technique in LNCaP cells, and identiﬁed a novel fusion
transcript comprising the RLN1 and RLN2 genes. The fusion transcript encodes a putative RLN2 with a deleted secretory signal
peptide indicating a potentially biologically important alteration.
We have unveiled an association between the expression and
regulation of RLN1-RLN2 fusion and RLN1, and discovered a surprising underrepresentation of RLN1 in PCa cell lines. Although
RLN1-RLN2 was identiﬁed in PCa cells, we show evidence of its
expression in normal prostate tissue. Further characterization of
the RLN1-RLN2 fusion product will shed new light on its role in PCa
as well as foster fundamental research in the ﬁeld.
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